Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

CHOICE clinical weight loss study

ABSTRACT: Evaluation of plasma samples from the CHOICE clinical weight loss study in which obese post menopausal breast cancer survivors lost >15% initial body weight following either a low carbohydrate or a low fat dietary pattern. These samples will be interrogated for changes in metabolic intermediates and lipid metabolites that may be indicative of changes in prognosis for long term survival following treatment for breast cancer. Samples will be subjected to LCMS and shotgun lipidomics. In parallel, plasma and mammary gland fat pad from an obese rat model for breast cancer in which rats were subjected to a parallel level of weight loss will also be interrogated using the same procedures in an effort to inform the interpretation of the clinical data.

ORGANISM(S): Human Homo Sapiens Homo Sapiens;rattus Norvegicus Rat Rattus Norvegicus

TISSUE(S): Blood

DISEASE(S): Obesity

SUBMITTER: Maureen Kachman

PROVIDER: ST000661 | MetabolomicsWorkbench | Mon Jun 05 00:00:00 BST 2017

REPOSITORIES: MetabolomicsWorkbench

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	mwtab	Other

Items per page:

1 - 1 of 1

Similar Datasets

Metabolomics Workbench ST000661 - GNPS - CHOICE clinical weight loss study

Project description:Evaluation of plasma samples from the CHOICE clinical weight loss study in which obese post menopausal breast cancer survivors lost >15% initial body weight following either a low carbohydrate or a low fat dietary pattern. These samples will be interrogated for changes in metabolic intermediates and lipid metabolites that may be indicative of changes in prognosis for long term survival following treatment for breast cancer. Samples will be subjected to LCMS and shotgun lipidomics. In parallel, plasma and mammary gland fat pad from an obese rat model for breast cancer in which rats were subjected to a parallel level of weight loss will also be interrogated using the same procedures in an effort to inform the interpretation of the clinical data.

2018-08-02 | MSV000082728 | GNPS

Single cell RNA sequencing of CD45+ immune cells from tumor and tumor-adjacent mammary adipose tissue in a postmenopausal breast cancer model of lean, obese, and weight loss Trem2+/+ and Trem2-/- mice

Project description:Triggering receptor expressed on myeloid cells 2 (Trem2) has been shown to be immunosuppressive in cancer and increased in obese adipose tissue. We utilized high fat and low fat diet to generate lean, obese, and weight loss mice in Trem2 wild-type (Trem2+/+) and Trem2 deficient (Trem2-/-) conditions. Once obesity and weight loss were established, mice were injected with E0771 breast cancer cells and tumors were allowed to grow for 4 weeks. We wanted to better understand the immune landscape of both the tumor and the surrounding adjacent mammary adipose tissue (mAT). Therefore, the CD45+ immune cells from both the tumor and tumor-adjacent mAT were isolated and sequenced using single-cell RNA sequencing and V(D)J sequencing.

2024-11-05 | GSE278003 | GEO

Expression data from murine colon tumors induced by azoxymethane. Tumors from control, obese, formerly obese, or sulindac-treated mice.

Project description:Obesity is associated with an increased risk of colon cancer. Our current study examines whether weight loss and/or treatment with the non-steroidal anti-inflammatory drug (NSAID) sulindac suppresses the protumor effects of obesity in a mouse model of colon cancer. Azoxymethane-treated male FVB/N mice were fed a low-fat diet (LFD) or high-fat diet (HFD) for 15 weeks, then HFD mice were randomized to remain on HFD (obese) or switch to LFD (formerly obese (FOb-LFD)). Within the control (LFD), obese, and FOb-LFD groups, half the mice were also randomized to start sulindac treatment (140 ppm in the diet). All mice were euthanized seven weeks later. FOb-LFD mice had intermediate levels of body weight, lower than obese but higher than control mice (P<0.05). Sulindac did not affect body weight. Obese mice had greater tumor multiplicity and burden than all other groups (P<0.05). Transcriptomic profiling indicated that both weight loss and sulindac modulate the expression of tumor genes related to invasion and may promote a more anti-tumor immune landscape. Furthermore, the fecal microbes Prevotella and Akkermansia muciniphila, both known to be elevated in colorectal cancer patients, were positively correlated with tumor multiplicity and reduced by sulindac in obese mice. In sum, either moderate weight loss or sulindac treatment completely reversed the effects of chronic obesity on colon tumorigenesis. Our findings suggest that an investigation regarding the effects of NSAID treatment on colon cancer risk and/or progression in obese individuals is warranted, particularly for those unable to achieve moderate weight loss.

2022-08-10 | GSE197846 | GEO

Calorie Restriction Outperforms Bariatric Surgery in Reversing Obesity-Driven Tumor Progression in a Mouse Model of Triple Negative Breast Cancer-RRBS

Project description:lean control, obese, and formerly obese C57BL6N mice which underwent weight loss via low-fat diet or verticle sleeve gastrectomy were injected with E0771 cells and tumor growth was monitored

2023-09-12 | GSE230473 | GEO

Calorie Restriction Outperforms Bariatric Surgery in Reversing Obesity-Driven Tumor Progression in a Mouse Model of Triple Negative Breast Cancer-RNAseq

2023-09-12 | GSE230472 | GEO

Calorie Restriction Outperforms Bariatric Surgery in Reversing Obesity-Driven Tumor Progression in a Mouse Model of Triple Negative Breast Cancer-Study1_tumor

Project description:lean control, obese, and formerly obese C57BL6N mice which underwent weight loss via vertical sleeve gastrectomy or low fat diet were injected with E0771 cells and tumor growth was monitored

2023-09-12 | GSE230470 | GEO

Various forms of calorie restriction, but not a nonrestricted low-fat diet, reverse obesity-associated tumor growth and lung metastasis in a mouse model of triple-negative breast cancer-RRBS

Project description:lean control, obese, and formerly obese C57BL6N mice which underwent weight loss via low-fat diet or various forms of calory restriction were injected with E0771 cells and tumor growth was monitored

2022-05-12 | GSE202331 | GEO

Various forms of calorie restriction, but not a nonrestricted low-fat diet, reverse obesity-associated tumor growth and lung metastasis in a mouse model of triple-negative breast cancer-RNAseq

2022-05-12 | GSE202330 | GEO

Weight loss resulted in increased expression of the anti-inflammatory protein, CRISPLD2, in mouse adipose tissue

Project description:Purpose: NGS was used to determine if a distinct transcriptomic profile is observed between lean, obese and weight loss fat Methods: We carried out RNA-Seq analysis of epididymal adipose mice ad libitum fed for 10 weeks either a high fat diet (HFD) or a regular chow diet (RD), versus a cohort of mice fed HFD for the first 5 weeks before swapping to RD for the remainder (SWAP). Results: SWAP feeding resulted in weight loss with a parallel improvement in insulin sensitivity. RNA-Seq revealed several transcriptomic signatures distinct to SWAP adipose, distinguished from both RD and HFD adipose. We found a unique up-regulated mRNA encoding a secreted, LPS-binding glycoprotein, CRISPLD2, in SWAP adipose tissue. While cellular CRISPLD2 protein levels were unchanged, plasma CRIPSLD2 levels increased in SWAP mice following weight loss, and can correlate with insulin sensitivity. Conclusions: Taken together, our data demonstrate that CRISPLD2 is a circulating adipokine that may regulate adipocyte remodeling during weight loss.

2019-08-02 | GSE135239 | GEO

Gene expression profiling of adipocyte and stromal vascular cells from adipose tissue in lean, obese and formerly obese mice

Project description:To investigate the transcriptional profiles of adipocytes and stromal vascular cells from mouse visceral adipose tissue(vWAT) in lean (Low fat diet, LFD fed), obese (high fat diet, HFD fed) and formerly obese (diet switch (SW) from 9 weeks HFD, to 3 weeks LFD) to induce weight loss.

2022-08-04 | GSE210014 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data